Navega Therapeutics
Ana Moreno is the founder and CEO of Navega Therapeutics. She obtained her Ph.D. from the Bioengineering Department at UCSD , where she spent the last four years developing the platform that enables Navega’s innovative approach.
Navega Therapeutics
Navega Therapeutics has developed a patented, non-permanent gene therapy to target pain that is non-addictive, highly specific, and long-lasting. Navega Therapeutics has imitated this process by utilizing a novel gene therapy to target pain in a non-permanent way.